Pre-made Onartuzumab benchmark antibody ( Fab + di-Fc, anti-MET therapeutic antibody, Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-401
Pre-Made Onartuzumab biosimilar, Fab + di-Fc, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Onartuzumab is a humanized monoclonal antibody designed for the treatment of advanced non-small-cell lung cancer.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Onartuzumab biosimilar, Fab + di-Fc, Anti-MET Antibody: Anti-AUTS9/DFNB97/HGFR/RCCP2/c-Met therapeutic antibody|
|Format||Fab + di-Fc|
|Highest_Clin_Trial (Jan '20)||Phase-III|
|100% SI Structure||4k3j:HL|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Breast cancer;Colorectal cancer;Gastric cancer;Glioblastoma;Liver cancer;Non-small cell lung cancer;Solid tumours|